8-K: Heartflow Soars with 40% Revenue Growth in Q4 2025

Heartflow, Inc. reported robust financial results for the fourth quarter and full year ended December 31, 2025, driven by accelerating adoption of its AI technology for coronary artery disease.

Summary

• Total revenue for Q4 2025 was $49.1 million, marking a 40% increase year-over-year.
• Full year 2025 total revenue reached $176.0 million, also a 40% increase year-over-year.
• Gross margin for Q4 2025 was 79.5% (GAAP) and 79.9% (non-GAAP), showing significant expansion.
• Full year 2025 gross margin was 76.8% (GAAP) and 77.0% (non-GAAP).
• Net operating loss for Q4 2025 was $17.8 million (GAAP) and $12.5 million (non-GAAP), an improvement in non-GAAP terms.
• Full year 2025 net operating loss was $64.1 million (GAAP) and $50.1 million (non-GAAP), also an improvement in non-GAAP terms.
• The U.S. installed base grew to 1,465 accounts for the Heartflow Platform and 489 accounts for Heartflow Plaque Analysis as of December 31, 2025.
• Aetna initiated coverage of Heartflow Plaque Analysis, extending total U.S. covered lives for Plaque to approximately 75%.
• Heartflow provided 2026 annual guidance projecting total revenue of $218 million to $222 million (24% to 26% growth year-over-year) and non-GAAP gross margin of 80% to 81%.
• The fourth quarter of 2025 is the last period for noncash charges related to common stock warrant liability remeasurement, as all warrants were fully exercised by October 22, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, driven by robust revenue growth, significant gross margin expansion, and positive developments in market access and future guidance, indicating solid operational execution and a clear path forward despite ongoing losses.

Positives

• Achieved 40% year-over-year revenue growth for both the fourth quarter and full year 2025, demonstrating strong market adoption.
• Realized significant gross margin expansion, with Q4 GAAP gross margin at 79.5% (up from 75.0%) and full year GAAP gross margin at 76.8% (up from 75.1%).
• Expanded the U.S. installed base to 1,465 accounts for the Heartflow Platform and 489 accounts for Plaque Analysis.
• Secured Aetna coverage for Heartflow Plaque Analysis, increasing total U.S. covered lives for Plaque to approximately 75%.
• Non-GAAP net operating loss and Adjusted EBITDA showed year-over-year improvement, indicating progress towards profitability.
• Provided strong 2026 annual guidance with projected revenue growth of 24% to 26% and non-GAAP gross margin of 80% to 81%.
• The full exercise of common stock warrants by October 22, 2025, eliminates future noncash charges from warrant revaluation.

Negatives

• Continued to report GAAP net operating losses of $17.8 million in Q4 2025 and $64.1 million for the full year 2025.
• Reported GAAP net losses of $24.4 million in Q4 2025 and $116.8 million for the full year 2025.
• Total operating expenses increased year-over-year due to increased investment in sales personnel, technology, and clinical research.

Risks

• May not be able to achieve or sustain profitability.
• Dependence on the success of its primary product, Heartflow FFRCT Analysis.
• Healthcare providers may be unwilling to change their standard practice regarding the evaluation of coronary artery disease.
• Adoption of the Heartflow Platform may be negatively impacted if third-party payors, including government payors, do not cover or provide adequate reimbursement.
• Concentration of the customer base.
• Significant competition in an environment of rapid technological change.
• Commercialization of Heartflow Plaque Analysis is nascent.
• Risks associated with the use and development of AI models.
• Risks related to failing to properly manage future growth.
• Disruption by catastrophic events.
• Risks associated with dependence on information technology systems.
• Security breaches that cannot be anticipated or successfully defended.
• Extensive regulatory requirements to bring products to market.
• Third parties could develop and commercialize technology and products similar or identical to Heartflow's.

Future Outlook

Heartflow projects total revenue for 2026 to be between $218 million and $222 million, representing approximately 24% to 26% year-over-year growth. Non-GAAP gross margin is expected to be between 80% and 81% for the full year 2026.

Management Comments

• "Our strong fourth quarter performance concluded a record year for Heartflow."
• "The accelerating adoption of the Heartflow Platform, combined with our disciplined execution across commercial, innovation, and clinical initiatives, drove 40% fourth quarter and full year revenue growth and record gross margins."
• "We also made significant strides in scaling account activations and driving early physician adoption of Heartflow Plaque Analysis."
• "Our 2026 guidance reflects strong business fundamentals, a solid foundation for growth, and high confidence in consistent execution."
• "With commercial, innovation and clinical catalysts on the horizon, our conviction in the business has never been higher."

Industry Context

StockSavvy.ai notes that Heartflow's continued strong revenue growth and expanding gross margins underscore the increasing adoption of AI-driven diagnostic tools in cardiovascular care. The expansion of insurance coverage, particularly with Aetna for Plaque Analysis, is a critical driver for market penetration and validates the clinical utility of Heartflow's technology in the broader healthcare ecosystem, positioning it as a leader in precision cardiovascular diagnostics.

Comparison to Industry Standards

• Heartflow's technology is adopted by more than 1,800 institutions globally, demonstrating significant market penetration for a specialized AI diagnostic tool.
• The platform is backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines, indicating strong clinical validation and acceptance within the medical community, a key differentiator in the diagnostic imaging sector.
• Heartflow's solutions are supported by over 600 peer-reviewed publications and validated through clinical evidence in over 200 studies assessing over 365,000 patients, which is a substantial body of evidence compared to many emerging medical technologies.
• The reported coronary CTA image acceptance rates exceeding 96% highlight the high reproducibility and accuracy of Heartflow's AI models in real-world practice, a crucial metric for diagnostic reliability.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, gross margin expansion, improved non-GAAP profitability metrics, and clear 2026 guidance. The full exercise of warrants removes future revaluation charges.
• Customers (Healthcare Providers): Benefit from the accelerating adoption of the Heartflow Platform and Plaque Analysis, supported by clinical evidence and seamless integration.
• Patients: Benefit from expanded access to Heartflow Plaque Analysis through Aetna coverage, enabling earlier detection and more precise management of coronary artery disease.
• Employees: Increased investment in sales personnel, technology, and clinical research suggests continued growth and opportunities.

Next Steps

• Host a conference call on March 18, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss financial results.
• Continue disciplined execution across commercial, innovation, and clinical initiatives.
• Leverage commercial, innovation, and clinical catalysts on the horizon for continued growth.

Key Dates

Recommendation

Heartflow's Q4 and full-year 2025 results demonstrate exceptional revenue growth of 40% and significant gross margin expansion, indicating strong market adoption and operational efficiency. The expansion of Aetna coverage for Plaque Analysis to 75% of U.S. covered lives is a major catalyst for future growth and market penetration. While the company continues to report GAAP losses, the improvement in non-GAAP metrics and the robust 2026 guidance (24-26% revenue growth, 80-81% non-GAAP gross margin) signal a clear trajectory towards profitability. The full exercise of warrants also removes a source of non-cash volatility. These factors, combined with a leading position in AI-driven cardiovascular diagnostics, make Heartflow a compelling 'strong buy' for investors seeking growth in the healthcare technology sector.

Keywords

Heartflow, HTFL, Financial Results, Q4 2025, Full Year 2025, Revenue Growth, Gross Margin, Net Operating Loss, Coronary Artery Disease, CAD, AI Technology, FFRCT, Plaque Analysis, Aetna Coverage, Medical Devices, Healthcare Technology, Earnings Report, Guidance